Posaconazole is an oral triazolic agent, nowadays formally recommended for primary antifungal prophylaxis (PAP) during induction chemotherapy for AML, that shows particularly strong activity as a CYP3A4 inhibitor [13]. This evidence concerns the gene CYP3A4 and acute myeloid leukemia.